Executive Summary
U.S. Drug Shortage Crisis
What Failed
A self-reinforcing structural cycle where race-to-the-bottom pricing drives offshore consolidation, enables systematic quality fraud at dominant facilities, and regulatory enforcement of quality standards triggers the very shortages those standards were meant to prevent. A single facility producing 30–50% of critical medications cannot be shut down without immediately creating nationwide shortage of life-saving therapies. This is the collection’s only chronic failure—the longest temporal lead and the only case where no single institutional actor possesses both the information and authority needed to break the cycle.
Structural Frequency Assessment
Critical
Pricing below $1/unit at manufacturer level; margins stripped below threshold for quality production; GPOs control 90% of hospital purchasing
Critical
Normalized quality fraud; Intas facility documented deliberate destruction of audit trails (acetic acid poured into analytical records)
Structural Departure
Domestic manufacturing capacity physically migrated offshore; China controls ~80% of APIs/KSMs; capability cannot be restored through information—must be rebuilt (5–10 years)
Critical
Pharmaceutical employment grew 20% but entirely in biologics/specialty; generic capacity hollowed underneath; headline metrics mask the structural gap
Key Evidence
300+ active shortages
At any given time (2024), from foundational chemotherapies to basic anesthetics
Single-facility concentration
Intas facility: ~50% of national supply of carboplatin and cisplatin; FDA enforcement would disrupt treatment for over 100,000 cancer patients
~80% API dependency on China
India imports 80% of APIs/KSMs from China; surface procurement metrics show diversification while underlying dependency remains concentrated
20-year structural unraveling
Chronic onset ~2001; Chinese state subsidies reached scale 2005–2010; no single correction event possible
Federal Data Validation
Structural signal crossed warning zone in 2006. Shortage counts did not spike above 200 until 2009. Composite peak: 0.54 (2023). Unique in the collection: chronic rather than acute failure, self-reinforcing feedback loop, no institutional actor with both information and authority to intervene.
Structural Mechanism
This case demonstrates the difference between acute and chronic structural failure. In SVB or Boeing, governance intervention could have changed the outcome. Here, the failure mode is self-reinforcing: pricing pressure drives offshoring, offshoring creates concentration, concentration creates quality risk, quality enforcement triggers shortage, shortage pressure reinforces pricing pressure. The cycle has no single point of intervention because the information needed to act and the authority needed to act reside in different institutions.